Robert Lynn, MD
Nephrology · Bronx, NYNPI 1851388862
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Baxter Healthcare at 44.3% of the total. Reporting peaked in 2019 at $8,865 and has fallen 95.5% since, to $401 in 2025. Among nephrology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $95.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$8K
- Amgen$5K
- Vifor Pharma, Inc.$2K
- AstraZeneca$583
- Akebia Therapeutics Inc$428
- Travere Therapeutics, Inc.$185
- plus $1K from 22 others
Across 235 payments — averaging $8573.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1M
- Boehringer Ingelheim International GmbH$272K
- GSK$245K
- Vertex$153K
- Astrazeneca UK Limited$134K
- CSL Behring$64K
- plus $141K from 8 others
What the payments were for
- Consulting fees$8,80048%
- Speaking & faculty fees$3,96022%
- Travel & lodging$9215%
- Food & beverage$4,55925%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 14 | $8,091 |
| Amgen(2 entities) | 41 | $5,402 |
| Vifor Pharma, Inc. | 26 | $2,186 |
| AstraZeneca | 30 | $583 |
| Akebia Therapeutics Inc | 20 | $428 |
| Travere Therapeutics, Inc. | 8 | $185 |
| Fresenius USA Marketing, Inc. | 7 | $164 |
| Vantive US Healthcare LLC | 1 | $145 |
| Calliditas Therapeutics US Inc. | 4 | $118 |
| Aurinia Pharma U.S., Inc. | 5 | $117 |
| Bard Peripheral Vascular, Inc. | 1 | $103 |
| Boehringer Ingelheim | 3 | $89 |
| Bayer | 4 | $84 |
| Lilly USA, LLC | 3 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $67 |
| GSK | 3 | $67 |
| Novo Nordisk | 3 | $60 |
| Novartis | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Ardelyx, Inc. | 2 | $31 |
| Pfizer | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Shield Therapeutics Inc | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Merck | 1 | $17 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - HD$7,751
- KRYSTEXXA$2,160
- EPOGEN$2,000
- Parsabiv$221
- Renal - PD$145
- Aranesp$103
- Tavneos$103
- COVERA$103
How this compares
$18,284 in reported general payments places this provider in the 90th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 67 | $219,837 |
| OzempicSemaglutide | 89 | $128,695 |
| FarxigaDapagliflozin Propanediol | 91 | $114,220 |
| VelphoroSucroferric Oxyhydroxide | 61 | $111,519 |
| MounjaroTirzepatide | 29 | $45,581 |
| AuryxiaFerric Citrate | 17 | $45,176 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $34,034 |
| KerendiaFinerenone | 22 | $28,774 |
| Sevelamer Carbonate | 56 | $23,863 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $22,448 |
| JardianceEmpagliflozin | 20 | $20,188 |
| TrulicityDulaglutide | 12 | $11,491 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $11,344 |
| Calcium Acetate | 57 | $7,138 |
| Novolog FlexpenInsulin Aspart | 28 | $5,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $583 | $148,254112 claims |
| Novo NordiskOzempic | $60 | $128,69589 claims |
| Fresenius USA Marketing, Inc.Velphoro | $164 | $111,51961 claims |
| Lilly USA, LLCMounjaro, Trulicity | $74 | $57,07341 claims |
| Akebia Therapeutics IncAuryxia | $428 | $45,17617 claims |
| BayerKerendia | $84 | $28,77422 claims |
| Boehringer IngelheimJardiance | $89 | $20,18820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 nephrology providers in New York.
Other nephrology in Bronx
- Bruce SpinowitzBronx$465K
- Joel NeugartenBronx$248K
- Enver AkalinBronx$101K
- John KangBronx$93K
- Daniel AddankiBronx$54K
- Chaim CharytanBronx$34K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.